
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Schrdinger, Inc. provides a physics-based software platform that enables the discovery of novel molecules for drug development and material applications. The company is headquartered in New York, New York.
| Revenue (TTM) | $259.04M |
| Gross Profit (TTM) | $147.31M |
| EBITDA | $-147.58M |
| Operating Margin | -70.60% |
| Return on Equity | -16.20% |
| Return on Assets | -14.40% |
| Revenue/Share (TTM) | $3.50 |
| Book Value | $4.21 |
| Price-to-Book | 4.00 |
| Price-to-Sales (TTM) | 5.02 |
| EV/Revenue | 3.897 |
| EV/EBITDA | -10.82 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 7.50% |
| Shares Outstanding | $65.64M |
| Float | $57.33M |
| % Insiders | 3.00% |
| % Institutions | 96.61% |
Volatility is currently expanding

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement t.

Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

Schrodinger NASDAQ: SDGR said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist.

NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Today Schrödinger announced financial results for the quarter ended June 30, 2026.

Schrödinger is challenging the incumbent drug-trial method—physics-simulated molecular design that cuts the cost, time, and animal testing of building and screening thousands of candidates. The current EV is roughly accounted for by the software leg alone - the royalties business and the disruption TAM are barely priced in, if at all. Three drivers - a regulatory push away from animal testing, AI-led consumption growth, and Bunsen - open up asymmetric upside that is not required for the base case.

NEW YORK--(BUSINESS WIRE)---- $SDGR #BunsenAI--Schrödinger, Inc. today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform,.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on July 16, 2026, the company granted restricted stock units (RSUs) with respect to 3,691 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to.

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SDGR and any ticker you trade — then tracks every position and per-strategy win rate.